Table 1 Demographic and clinical features—all patients.

From: Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes

Characteristic

All n = 1136

S-Phase <2% n = 372

S-Phase ≧2% n = 142

No/few monotypic plasma cells n = 622

ap-value

Age, median (IQR)

63 (56–68)

63 (56–67)

62.5 (57–69)

63 (56–68)

0.27

Sex, % male

59.2

60.7

62.6

57.5

0.76

Any HRCA, n (%)

508(44.7)

119(31.9)

85(59.8)

304(48.8)

<0.0001

 Deletion 17p

146(12.8)

31(8.3)

35(24.6)

80(12.8)

<0.0001

 1q gain/amplification

370 (32.5)

86(23.1)

58(40.8)

226(36.3)

<0.0001

 t(4:14)

114(10)

16(4.3)

18(12.6)

80(12.8)

<0.0009

 t(14:16)

44(3.8)

6(1.6)

9(6.3)

29(4.6)

0.0057

 t(14:20)

15(1.3)

3(0.8)

5(3.5)

7(1.1)

0.0337

 Unknown

119(10.4)

20(5.3)

15(10.5)

84(13.5)

 

ISS Stage, n (%)

 Low (I)

331(29.1)

132(35.4)

31(21.8)

168(27)

0.0048b

 Intermediate (II)

312(27.4)

100(26.8)

42(29.5)

170(27.3)

 High (III)

272(23.9)

72(19.3)

45(31.6)

155(24.9)

 Unknown

221(19.4)

68(18.2)

24(16.9)

129(20.7)

 

 Cr ≧2 mg/dl, n (%)

155(13.6)

32(8.6)

26(18.3)

97(15.5)

0.0044

Induction therapy n (%)

 Doublet

31(2.7)

19(5.1)

8(5.6)

4(0.6)

0.6287c

 Triplet

805(70.8)

277(74.4)

102(71.8)

426(68.4)

 Quadruplet

300(26.4)

76(20.4)

32(22.5)

192(30.8)

 Unknown

0

0

0

0

 

Disease response at transplantation, n (%)

 <VGPR

342(30)

235(63.1)

59(41.5)

48(7.7)

<0.0001

 ≧VGPR

787(69.2)

137(36.8)

83(58.4)

567(91.1)

 Unknown

7(0.6)

0

0

7(1.1)

 

Maintenance therapy n (%)

 No maintenanced

89(7.8)

42(11.3)

19(13.4)

28(4.5)

0.5339

 IMiD

568(50)

198(53.2)

53(37.3)

317(50.9)

 PI

159(13.9)

44(11.8)

19(13.3)

96(15.4)

 IMiD+PI

170(14.9)

38(10.2)

28(19.7)

104(16.7)

 Anti CD38-based

113(9.9)

38(10.2)

13(9.1)

62(9.9)

 Unknown

10(0.8)

4(1)

0

6(0.9

 
  1. HRCA high-risk cytogenetic abnormalities, ISS International Staging System, IQR interquartile range, Cr creatinine, PI proteasome inhibitor, IMiD immunomodulatory drug, ASCT autologous stem cell transplantation, VGPR very good partial response, NR not reached.
  2. aP-values compare groups with S-phase <2% versus S-phase ≥2%.
  3. bP-value calculated between ISS stage I/II versus III among patients with available S-phase.
  4. cP-value calculated between doublet/triplet versus quadruplet induction therapy among patients with available S-phase.
  5. dPatients who relapsed within 100 days and didn’t get maintenance therapy were excluded. 8 patients from the <2% group and 10 from the ≥2% and 9 from the no/few monotypic plasma cells group.
Back to article page